FDA Approves Tremfya for Active Crohn Disease in Adults
The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for adult patients with moderately to severely active ...
FDA approves Tremfya for active Crohn's disease in adults
The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for adult patients with ...
Rheumatology Advisor2d
Tremfya Approved for Moderately to Severely Active Crohn Disease
The FDA has approved Tremfya (guselkumab) for the treatment of adults with moderately to severely active Crohn disease.
Fierce Pharma9d
J&J advances Stelara succession scheme with FDA nod for Tremfya in Crohn's disease
With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...
FDA Approves Johnson & Johnson's Tremfya For Crohn's Disease
Johnson & Johnson's Tremfya gains FDA approval for Crohn's disease, backed by Phase 3 trial data and demonstrating ...
Medscape5d
FDA OKs Guselkumab for Crohn’s Disease
Guselkumab is the first and only interleukin-23 inhibitor that offers both subcutaneous and intravenous induction options for ...
Healio9d
Tremfya’s FDA win as fully subcutaneous option for Crohn’s may pave way to eclipse Stelara
The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...
Monthly Prescribing Reference9d
Tremfya Approved for Moderately to Severely Active Crohn Disease
Tremfya is the only IL-23 inhibitor with IV and SC induction options for treating Crohn disease. The Food and Drug Administration (FDA) has approved Tremfya ® (guselkumab) for the treatment of ...
Yahoo Finance9d
J&J's Tremfya Gets FDA Nod for 2nd IBD Condition Crohn's Disease
Johnson & Johnson JNJ announced that the FDA has granted approval to its key drug, Tremfya, for its second inflammatory bowel disease (IBD) condition — moderately to severely active Crohn’s ...